Stoke Therapeutics Q2 2025 Earnings Call: Dravet Syndrome Drug Updates

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

08/07/2025 - 07:00 AM

BEDFORD, Mass.--(BUSINESS WIRE)-- (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body鈥檚 potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30 p.m. ET, to discuss second quarter 2025 business and financial updates.

The webcast will be available on the Investors & News section of Stoke鈥檚 website at . Research analysts who plan to join the call and participate in the Q&A session may register to receive the dial-in details and a unique PIN. All other participants are invited to access the listen-only webcast by clicking . An archived replay of the webcast will be available for at least 90 days following the event.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body鈥檚 potential with RNA medicine. Using Stoke鈥檚 proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke鈥檚 first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke鈥檚 initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke鈥檚 proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit .